Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Osteoarthritis in 2016

Anti-NGF treatments for pain — two steps forward, one step back?

Nature Reviews Rheumatology volume 13, pages 76–78 (2017)Cite this article

Subjects

Inhibitors of β-nerve growth factor (NGF) have impressive effects in reducing musculoskeletal pain, but have also been associated with adverse events of unclear aetiology. Several studies in the past year have sought to clarify the relative benefits and risks of anti-NGF treatment.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Transmission of pain by NGF.

References

  1. Eibib, J., Strasser, B. C. & Ross, G. M. Structural, biological, and pharmacological strategies for the inhibition of nerve growth factor. Neurochem. Int. 6, 1266–1275 (2012).

    Google Scholar 

  2. Schnitzer, T. J. & Marks, J. A. A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip and knee. Osteoarthritis Cartilage 23 (Suppl. 1), S8–S17 (2015).

    Article  Google Scholar 

  3. Lane, N. E. et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N. Engl. J. Med. 363, 1521–1531 (2010).

    Article  CAS  Google Scholar 

  4. Hochberg, M. C. et al. When is osteonecrosis not osteonecrosis? Adjudication of reported serious adverse joint events in the tanezumab clinical development program. Arthritis Rheumatol. 68, 382–391 (2016).

    Article  CAS  Google Scholar 

  5. Maloney, J. et al. Efficacy and safety of fasinumab for osteoarthritic pain in patients with moderate to severe osteoarthritis of the knees or hips [abstract]. Arthritis Rheumatol. 68 (Suppl. 10), 295 (2016).

    Google Scholar 

  6. Regeneron Pharmaceuticals. Regeneron and Teva provide update on fasinumab clinical development programs. PR Newswire http://www.prnewswire.com/news-releases/regeneron-and-teva-provide-update-on-fasinumab-clinical-development-programs-300345603.html (2016).

  7. Prencipe, G. et al. Nerve growth factor downregulates inflammatory response in human monocytes through TrkA. J. Immunol. 192, 3345–3354 (2014).

    Article  CAS  Google Scholar 

  8. Krock, E. et al. Nerve growth factor is regulated by Toll-like receptor 2 in human intervertebral discs. J. Biol. Chem. 291, 3541–3551 (2016).

    Article  CAS  Google Scholar 

  9. Wirz, S. A., Tobias, P. S., Ulevitch, R. J., Aribibe, L. & Bartfai, T. TLR2 is required for the altered transcription of p75NGF receptors in Gram positive infection. Neurochem. Res. 31, 297–301 (2006).

    Article  CAS  Google Scholar 

  10. Jiang, Y. et al. Nerve growth factor promotes TLR4 signaling-induced maturation of human dendritic cells in vitro through inducible p75NTR 1. J. Immunol. 179, 6297–6304 (2007).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Center for Musculoskeletal Health, University of California at Davis School of Medicine, 4625 2nd Avenue, Sacramento, 95817, California, USA

    Nancy E. Lane

  2. Department of Medicine, University of California at San Diego, 9500 Gilman Drive, La Jolla, 92093–0663, California, USA

    Maripat Corr

Authors
  1. Nancy E. Lane
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maripat Corr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nancy E. Lane.

Ethics declarations

Competing interests

N.E.L. declares that she is a consultant to and advisory board member for Regeneron. M.C. declares no competing interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lane, N., Corr, M. Anti-NGF treatments for pain — two steps forward, one step back?. Nat Rev Rheumatol 13, 76–78 (2017). https://doi.org/10.1038/nrrheum.2016.224

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2016.224

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research